Differentiation of autologous stem cells into functional transplantable tissue for organ regeneration is a promising regenerative therapeutic approach for cancer, diabetes, and many human diseases. Yet to be established, however, is differentiation into tissue capable of producing erythropoietin (EPO), which has a critical function in anemia. We report a novel EPO-producing organ-like structure (organoid) derived from human mesenchymal stem cells. Using our previously established relay culture system, a human mesenchymal stem cell-derived, human EPO-competent organoid was established in rat omentum. The organoid-derived levels of human EPO increased in response to anemia induced by rapid blood withdrawal. In addition, the presence of an organoid in rats suppressed for native (rat) EPO production enhanced recovery from anemia when compared with control animals lacking the organoid. Together these results confirmed the generation of a stem cell-derived organoid that is capable of producing EPO and sensitive to physiological regulation.
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(Transplantation 2008;85: 1654-1658) E rythropoietin (EPO) stimulates red blood-cell production and is produced mainly in the kidneys. Recombinant human EPO is widely administered to treat and mitigate renal anemia in chronic renal failure (CRF) patients (1), improving quality of life and reducing mortality and morbidity (2, 3) . In fact, costly recombinant human EPO treatment (more than $9,000 per person per year) accounts for the highest annual drug sales worldwide (4) . In light of the predicted rise in CRF in aging populations globally, the need to develop a cost-effective alternative is apparent. Transplanting EPOproducer from a human source seems to be the ideal therapeutic focus for CRF because it would be more cost effective and less likely to result in the serious complication of pure red-cell aplasia, because of the possibility of auto-regulation.
Treatment successes have been reported with gene therapy (5) , in which the EPO gene is transferred directly to the recipient in vivo, and cell therapy (6) , which involves putting the EPO gene into isolated cells that are then transplanted into the recipient organism, in combination with an artificial regulatory system (7-10). These methods, however, require viral vector-mediated delivery, which carries ethical issues and may not adequately mimic the physiological oxygen-dependent control of EPO production due to its complex and sensitive regulation in vivo (4) . The ultimate therapeutic approach, then, is to establish functional tissue derived from human autologous stem cells, capable of generating endogenous levels of HuEPO and retaining physiological regulatory pathways to deal with conditions such as anemia. We therefore attempted to establish the transplantable HuEPO producer from human mesenchymal stem cells (hMSCs).
transfected with glial cell-derived neurotrophic factor (GDNF) using AxCAhGDNF (12) and subsequently injected at the site of kidney organogenesis of growing rat embryo (E11.5) (Supplementary Fig. 1 and Movie, available for viewing online only). GDNF is normally expressed in metanephric mesenchyme at this stage, and the interaction between GDNF and its receptor, c-ret, is required for epithelial-mesencymal signaling (13) . Whole embryo was then cultured according to the whole embryo culture system described previously (14) , and kidney rudiments were dissected for metanephric organ culture for 24 h (15). We previously confirmed that this relayculture system is able to differentiate exogenous hMSCs into kidney structure comprising tubular and glomerular epithelial cells as well as interstitial cells (11), where EPO is physiologically produced (16) . Resultant kidney rudiments were transplanted in the omentum of host rats (Sprague-Dawley; Sankyo Laboratory Service, Tokyo, Japan) and during the same surgery, host rats had the right kidney removed to enhance the development of kidney rudiment (17) . It was previously reported that metanephros transplanted into omentum evokes minimal immunogenicity (18) . In support of this, we found a negligible number of mononuclear cells infiltrating the established organoid even 4 weeks after transplantation (data not shown). This additional development in the omentum may lead to vascular integration of the host circulation into the transplanted kidney rudiment (19) (resultant kidney-like structure was termed organoid). Detailed methods for establishing organoid are provided separately in the on-line Supporting Information.
Production of Human Erythropoietin From Organoid
Real-time polymerase chain reaction of RNA extracted from organoid tissue 2 weeks after implantation indicated the expression of both human and rat EPO mRNA (Fig. 1A) ; EPO was not expressed in the kidney rudiment before transplantation. This finding suggested that reciprocal interactions between stromal cells in the transplant and integrated endothelial cells are important for the differentiation of EPOproducing cells. In addition, the organoid must acquire the potential for EPO production during development in the recipient omentum. Sequence analysis using a BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Faster City, CA) confirmed the expressed EPO gene product to be of human and rat origin, showing that the established organoid could produce both human and rat EPO, probably reflecting the chimeric nature of the organoid (11) (Fig. 1B) . Immunohistochemical staining with an antibody to HuEPO (Santa Cruz, CA) further confirmed that the organoid contained EPO-producing cells (Fig. 1C) . The HuEPO antibodies crossreact with rat EPO, whereas the antibody for ␤2-microgloblin (h␤2MG; BD Biosciences, San Diego, CA) is human-specific (data not shown). We therefore double stained for h␤2MG and EPO, revealing that some h␤2MG-immunopositive cells also expressed HuEPO (Fig. 1D) . These data clearly indicated that exogenous hMSCs may develop into HuEPO-producing cells during culture in a growing embryo or host omentum, and that the new tissue is chimeric. Histochemical analysis demonstrated that approximately 30% of the EPOproducing cells were generated from hMSCs.
Physiological Regulation of Human Erythropoietin Production
To confirm that increased levels of EPO mRNA corresponded to elevated EPO protein in the serum, both host kidneys were removed to mask native EPO induction, and then anemia was induced by a rapid withdrawal of blood from the vena cava at a volume of 2% v/w body weight (20) . Serum EPO levels were measured using RIA kit (Mitsubishi Kagaku Iatoron, Tokyo, Japan) 24 hr later, when EPO production peaks after the induction of anemia (data not shown). Rats with two functional kidneys were examined first as overall controls, and showed significantly elevated serum EPO levels in response to anemia induction. In contrast, the anephric rats with no organoid transplanted showed no change in serum EPO after induction of anemia, indicating that hepatic EPO production was insufficient to affect peripheral levels, whereas serum EPO levels were partially restored to significant levels in rats harboring an organoid ( Fig. 2A) . Notably, no significant difference in serum EPO levels was detected between the anephric rats with or without an organoid before anemia induction, strongly suggesting that EPO production by the organoid was not autonomous, but rather was suppressed in the absence of anemia. Because the RIA using the cross-reactive antibody to EPO could not distinguish human and rat EPO, we conducted real-time polymerase chain reaction experiments using a human-specific probe and primer to confirm that HuEPO was truly elevated in response to anemia induction. The TaqMan MGB probes and primers for HuEPO were designed by Primer Express Software (version 3.0, Applied Biosystems). The primers and the probe sequences were as follows: HuEPO-forward, 5Ј AGC CCA GAA GGA AGC CAT CT 3Ј; HuEPO-reverse, 5Ј GCG GAA AGT GTC AGC AGT GAT 3Ј; hEPO TaqMan-MGB probe, 5Ј FAM-CCC TCC AGA TGC GGC CTC AGC T-MGB 3Ј (bold letters show the sequence differences between human and rat EPO). The human BUBR1 gene, which is constantly transcribed, was used as a human cell-specific endogenous control (21) . The TaqMan probe and primers for human BUBR1 were assay-on-demand gene expression products (Applied Biosystems assay identification number Hs00176169_m1). The sets of human-specific TaqMan probes and primers were not cross-reactive with rat EPO or rat BUBR1. Relative amounts of human-specific EPO cDNA were estimated by its amount relative to the amount of BUBR1 cDNA. Relative ratios of HuEPO to endogenous mRNA were compared before and after anemia induction (nϭ8 in each group). Human-specific EPO production was indeed enhanced by anemia induction (43.39%Ϯ2.36% no anemia vs. 66.77%Ϯ2.39%ϩanemia; Pϭ0.0043). These data suggested that HuEPO producing cells are responsive to anemia.
Physiological Activity of Human Erythropoietin Derived From Organoid
We next analyzed whether EPO produced by the organoid reached sufficient physiological levels to affect the recovery from induced anemia. As the anephric rat died within 3 days, we generated a second group of experimental rats (Wister/Kyoto, Charles River, Yokohama, Japan) to address this issue. Native EPO production in these rats with or without organoid was suppressed by induction of nephritis with heminephrectomy. Two weeks later after the surgery of implantation of kidney rudiment and heminephrectomy, the rats were injected with anti-glomerular basement membrane antibody to induce nephritis as previously described (22) , and then another 2 weeks later, anemia was induced. Histological analysis showed renal crescent formation and severe interstitial damage with suppressed potential for EPO production in the doubly treated rats (nephritis and heminephrectomy; Supplementary Fig. 2, available for viewing online only) . Because EPO production peaked within 24 hr after anemia induction in each group, the amount produced by the doubly treated rats was sufficient to recover anemia within 10 days. We thus compared the kinetics of recovery from anemia in anephric rats with or without organoid. Normal kinetics of recovery from anemia was also established in age-matched rats with native kidney and without organoid. The time course of recovery from anemia in the EPO-suppressed rats was much slower than in control rats with both kidneys. In comparison, and importantly, native EPO-suppressed rats that harbored an hMSC-derived organoid in their omentum FIGURE 1. Production of human erythropoietin (HuEPO) from organoid derived from human mesenchymal stem cells (hMSCs). (A) The organoid was established from hMSCs using the modified relay-culture system. RNA was extracted, and the expression of human and rat EPO mRNA was examined by RT-PCR as previously described (23, 24) . exhibited a similar rate of recovery from induced anemia to control rats (Fig. 2B) . Although renal anemia in humans is more chronic compared with the acute insult we examined here, these data suggest that the organoid-derived EPO production was physiologically functional in response to induced anemia. We are currently establishing a system whereby unnecessary EPO-producing cells can be eliminated using a suicide gene under the control of an inducible promoter.
CONCLUSION
We report three major findings from establishing hMSC-derived organoid in rats: (1) HuEPO is produced in rats harboring an organoid derived from autologous human bone marrow cells; (2) HuEPO production is stimulated by induction of anemia, suggesting that this system preserves the normal physiological regulation of EPO levels; and, (3) levels of EPO generated by the organoid in response to anemia are sufficient to restore red cell recovery in rats suppressed for native EPO production to a rate similar to that of control rats.
The results presented here have promising implications for developing effective therapies. Use of a transplantable organoid derived from hMSCs would eliminate the need for immunosuppressants if transplanted in the omentum of a patient from whom the bone marrow stem cells were isolated, thus addressing one of the major obstacles (tissue rejection) of such therapies. This work could spurn a new generation of therapy modalities for renal anemia. FIGURE 2. EPO production from organoid and its contribution to erythropoiesis. (A) Anemia was induced in the anephric rats with or without the organoid implanted in the omentum (nϭ8 each group). Serum EPO levels were subsequently measured by RIA. As a control, EPO levels were measured in anemia-induced rats retaining both native kidneys (nϭ8). (B) Anemia was induced in a second group of rats with their EPO production from the native kidneys minimized by glomerular basement membrane (GBM)-induced nephritis and heminephrectomy. Recovery from anemia in these doubly treated rats with or without the EPO-generating organoid was analyzed by hematocrit (Ht) levels (upper panel, nϭ30 in each group) and hemoglobin (Hb) levels (lower panel, nϭ4 -30 in each group). Rats with both native kidneys induced for anemia were used as controls (nϭ34). (*Pϭ0.033; **Pϭ0.072, ***Pϭ0.012 between rats with and without organoid, respectively).
